-+ 0.00%
-+ 0.00%
-+ 0.00%

ORYZON RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL TO INITIATE THE HOPE-2 PHASE II STUDY OF VAFIDEMSTAT FOR THE TREATMENT OF PHELAN-MCDERMID SYNDROME (PMS)

路透·09/28/2026 12:00:02

請登錄查看新聞詳情